GAITHERSBURG, Md. - Emergent BioSolutions Inc. (NYSE: EBS), whose stock has surged over 250% in the past year and is currently considered undervalued according to InvestingPro analysis, has been granted a $50 million option under an existing contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) for the procurement of its CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) vaccine. The company, with a market capitalization of approximately $460 million, announced today that the deliveries of the vaccine are slated to commence this year and conclude by April 2025.Want deeper insights? InvestingPro subscribers have access to 8 additional expert tips and comprehensive financial analysis for EBS.
This contract option follows a prior $30 million modification to supply the CYFENDUS® vaccine. The vaccine, which received U.S. Food & Drug Administration (FDA) approval in July 2023, is designed for post-exposure prophylaxis in individuals aged 18 to 65 years following suspected or confirmed exposure to Bacillus anthracis, the bacterium that causes anthrax.
Anthrax is classified as a Tier 1 biological select agent and is considered a significant threat to public health and national security due to its potential for widespread impact and ease of dissemination. Paul Williams, senior vice president of products at Emergent, stated that the procurement award reinforces anthrax preparedness and reflects the company's commitment to public health preparedness.
Emergent's portfolio also includes the BioThrax® vaccine and two anthrax treatments, Anthrasil® [Anthrax Immune Globulin Intravenous (Human)] and raxibacumab, a monoclonal antibody therapeutic. The federal funding for this project has been provided in whole or in part by BARDA under contract HHSO100201600030C.
CYFENDUS® is indicated for use in conjunction with recommended antibacterial drugs and is based on efficacy studies conducted in animal models. The vaccine is contraindicated for those allergic to any of its ingredients and should be administered with caution to immunocompromised individuals. The most commonly reported adverse reactions include injection site reactions, muscle aches, fatigue, and headaches.
This news is based on a press release statement from Emergent BioSolutions Inc. The company, which has been operating for 25 years, focuses on developing and manufacturing vaccines and therapeutics for public health threats and offers a range of contract development and manufacturing services. With annual revenue of $1.13 billion, the company continues to invest in growth despite current unprofitability.Access the complete financial health analysis and detailed Fair Value calculations for EBS and 1,400+ other stocks through InvestingPro's comprehensive research reports.
In other recent news, biopharmaceutical company Emergent BioSolutions Inc. has released its third-quarter results for 2024. The company's Assistant Treasurer, Frank Vargo, led a conference call discussing the operational and financial performance, while also providing some insights into future outlook. Emergent BioSolutions stressed that any forward-looking statements are dependent on current expectations and could be subject to change.
The call did not present any specific bearish or bullish information, nor were any significant misses mentioned. The company also conducted a question-and-answer session, specifics of which were not included in the provided context.
Emergent BioSolutions reminded investors of the cautionary statements and risk factors associated with these projections, as detailed in their periodic reports filed with the Securities and Exchange Commission (SEC). It was evident from the call that Emergent BioSolutions remains committed to transparency and providing stakeholders with the necessary information to understand the company's direction and potential future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.